CREB5 promotes tumorigenicity and upregulates druggable cell surface modalities in basal-like breast cancer

Allison Makovec; Ella Boytim; Ava Gustafson; Megan Ludwig; Liangjun Wang; Atef Ali; Khalid Ishani; Christine Luo; Hannah E. Bergom; Emily John; Sydney Tape; Samuel Kellen; Aiden Deacon; Fatemah Iman Dewji; Camden Richter; Lauren Cookle; David Moline; Jonathan P. Rennhack; Justin M. Drake; Emmanuel S. Antonarakis; David A. Largaespada; Julie H. Ostrander; Justin Hwang

doi:10.1038/s41698-025-01051-z

CREB5 promotes tumorigenicity and upregulates druggable cell surface modalities in basal-like breast cancer

Allison Makovec, Ella Boytim, Ava Gustafson, Megan Ludwig, Liangjun Wang, Atef Ali, Khalid Ishani, Christine Luo, Hannah E. Bergom, Emily John, Sydney Tape, Samuel Kellen, Aiden Deacon, Fatemah Iman Dewji, Camden Richter, Lauren Cookle, David Moline, Jonathan P. Rennhack, Justin M. Drake, Emmanuel S. AntonarakisDavid A. Largaespada, Julie H. Ostrander, Justin Hwang

Research output: Contribution to journal › Article › peer-review

Abstract

Basal-like breast cancers (BLBC) have limited targeted therapies and poor outcomes. We found that CREB5 is a transcription factor overexpressed in 15% of BLBCs and was upregulated in breast cancers that metastasize to the brain. In cell lines, CREB5 overexpression regulated cell phenotypes and transcriptional changes, including IL13RA2, a cell surface receptor that is currently druggable and represents a novel target in BLBC.

Original language	English (US)
Article number	276
Journal	npj Precision Oncology
Volume	9
Issue number	1
DOIs	https://doi.org/10.1038/s41698-025-01051-z
State	Published - Dec 2025

Bibliographical note

Publisher Copyright:
© The Author(s) 2025.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1038/s41698-025-01051-z

Find It

Find It at U of M Libraries

Cite this

Makovec, A., Boytim, E., Gustafson, A., Ludwig, M., Wang, L., Ali, A., Ishani, K., Luo, C., Bergom, H. E., John, E., Tape, S., Kellen, S., Deacon, A., Dewji, F. I., Richter, C., Cookle, L., Moline, D., Rennhack, J. P., Drake, J. M., ... Hwang, J. (2025). CREB5 promotes tumorigenicity and upregulates druggable cell surface modalities in basal-like breast cancer. npj Precision Oncology, 9(1), Article 276. https://doi.org/10.1038/s41698-025-01051-z

Makovec, A, Boytim, E, Gustafson, A, Ludwig, M , Wang, L, Ali, A, Ishani, K, Luo, C, Bergom, HE, John, E, Tape, S, Kellen, S, Deacon, A, Dewji, FI, Richter, C, Cookle, L, Moline, D, Rennhack, JP, Drake, JM , Antonarakis, ES , Largaespada, DA , Ostrander, JH & Hwang, J 2025, 'CREB5 promotes tumorigenicity and upregulates druggable cell surface modalities in basal-like breast cancer', npj Precision Oncology, vol. 9, no. 1, 276. https://doi.org/10.1038/s41698-025-01051-z

@article{25f248a7a818441d974141c980524f1a,

title = "CREB5 promotes tumorigenicity and upregulates druggable cell surface modalities in basal-like breast cancer",

abstract = "Basal-like breast cancers (BLBC) have limited targeted therapies and poor outcomes. We found that CREB5 is a transcription factor overexpressed in 15\% of BLBCs and was upregulated in breast cancers that metastasize to the brain. In cell lines, CREB5 overexpression regulated cell phenotypes and transcriptional changes, including IL13RA2, a cell surface receptor that is currently druggable and represents a novel target in BLBC.",

author = "Allison Makovec and Ella Boytim and Ava Gustafson and Megan Ludwig and Liangjun Wang and Atef Ali and Khalid Ishani and Christine Luo and Bergom, \{Hannah E.\} and Emily John and Sydney Tape and Samuel Kellen and Aiden Deacon and Dewji, \{Fatemah Iman\} and Camden Richter and Lauren Cookle and David Moline and Rennhack, \{Jonathan P.\} and Drake, \{Justin M.\} and Antonarakis, \{Emmanuel S.\} and Largaespada, \{David A.\} and Ostrander, \{Julie H.\} and Justin Hwang",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2025.",

year = "2025",

month = dec,

doi = "10.1038/s41698-025-01051-z",

language = "English (US)",

volume = "9",

journal = "npj Precision Oncology",

issn = "2397-768X",

publisher = "Nature Research",

number = "1",

}

TY - JOUR

T1 - CREB5 promotes tumorigenicity and upregulates druggable cell surface modalities in basal-like breast cancer

AU - Makovec, Allison

AU - Boytim, Ella

AU - Gustafson, Ava

AU - Ludwig, Megan

AU - Wang, Liangjun

AU - Ali, Atef

AU - Ishani, Khalid

AU - Luo, Christine

AU - Bergom, Hannah E.

AU - John, Emily

AU - Tape, Sydney

AU - Kellen, Samuel

AU - Deacon, Aiden

AU - Dewji, Fatemah Iman

AU - Richter, Camden

AU - Cookle, Lauren

AU - Moline, David

AU - Rennhack, Jonathan P.

AU - Drake, Justin M.

AU - Antonarakis, Emmanuel S.

AU - Largaespada, David A.

AU - Ostrander, Julie H.

AU - Hwang, Justin

PY - 2025/12

Y1 - 2025/12

N2 - Basal-like breast cancers (BLBC) have limited targeted therapies and poor outcomes. We found that CREB5 is a transcription factor overexpressed in 15% of BLBCs and was upregulated in breast cancers that metastasize to the brain. In cell lines, CREB5 overexpression regulated cell phenotypes and transcriptional changes, including IL13RA2, a cell surface receptor that is currently druggable and represents a novel target in BLBC.

AB - Basal-like breast cancers (BLBC) have limited targeted therapies and poor outcomes. We found that CREB5 is a transcription factor overexpressed in 15% of BLBCs and was upregulated in breast cancers that metastasize to the brain. In cell lines, CREB5 overexpression regulated cell phenotypes and transcriptional changes, including IL13RA2, a cell surface receptor that is currently druggable and represents a novel target in BLBC.

UR - https://www.scopus.com/pages/publications/105012737324

UR - https://www.scopus.com/inward/citedby.url?scp=105012737324&partnerID=8YFLogxK

U2 - 10.1038/s41698-025-01051-z

DO - 10.1038/s41698-025-01051-z

M3 - Article

C2 - 40770411

AN - SCOPUS:105012737324

SN - 2397-768X

VL - 9

JO - npj Precision Oncology

JF - npj Precision Oncology

IS - 1

M1 - 276

ER -

CREB5 promotes tumorigenicity and upregulates druggable cell surface modalities in basal-like breast cancer

Abstract

Bibliographical note

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this